Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


AbbVie showcases breadth and depth of research in Crohn’s disease and ulcerative colitis at UEG Week 2023

Written by | 14 Oct 2023

AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie… read more.

Skyrizi met all primary and secondary endpoints versus Stelara in head-to-head study in Crohn’s disease – AbbVie

Written by | 16 Sep 2023

AbbVie announced top-line results from the Phase III SEQUENCE clinical trial evaluating risankizumab (Skyrizi, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg… read more.

EU approves Aquipta for prophylaxis of migraine – AbbVie

Written by | 23 Aug 2023

AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.

Vyalev a continuous subcutaneousinfusion for Parkinson’s disease is now launched in Japan – AbbVie

Written by | 1 Aug 2023

AbbVie has launched Vyalev (foslevodopa + foscarbidopa), a continuous subcutaneous infusion for Parkinson’s disease, in Japan on July 26. This is the first Parkinson’s drug in the country… read more.

Positive CHMP opinion for atogepant for the preventive treatment of adults with migraine – AbbVie

Written by | 29 Jun 2023

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.

EU approves Rinvoq in Crohn’s disease – AbbVie

Written by | 1 Jun 2023

AbbVie announced the European Commission (EC) approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK)… read more.

Supplemental New Drug Application submitted to FDA for Vraylar for the adjunctive treatment of major depressive disorder – AbbVie

Written by | 10 Apr 2022

AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.

AbbVie provides update on Rinvoq for the treatment of rheumatoid arthritis in the U.S

Written by | 30 Jan 2022

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This… read more.

FDA approves Vuity for presbyopia – Allergan / AbbVie

Written by | 2 Nov 2021

Allergan announced the FDA approval of Vuity (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. Vuity is… read more.

FDA approves Qulipta for prevention of migraine – AbbVie

Written by | 19 Oct 2021

The FDA has approved Qulipta (atogepant tablets), from AbbVie, for the preventive treatment of episodic migraine in adults. The approval of Qulipta was based on findings from the… read more.

European Commission approval for Venclyxto + a hypomethylating agent for newly diagnosed acute myeloid leukemia – AbbVie

Written by | 3 Jun 2021

AbbVie announced that the European Commission (EC) has approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.